Keros Therapeutics, Inc. (KROS)
11.06
-0.02
(-0.23%)
USD |
NASDAQ |
Sep 01, 16:00
11.06
0.00 (0.00%)
After-Hours: 19:41
Keros Therapeutics Total Long Term Debt (Quarterly) : 13.13M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 13.13M |
| March 31, 2026 | 13.81M |
| December 31, 2025 | 14.48M |
| September 30, 2025 | 15.11M |
| June 30, 2025 | 15.72M |
| March 31, 2025 | 16.31M |
| December 31, 2024 | 16.88M |
| September 30, 2024 | 17.43M |
| June 30, 2024 | 12.86M |
| March 31, 2024 | 13.15M |
| December 31, 2023 | 13.44M |
| September 30, 2023 | 13.70M |
| June 30, 2023 | 13.95M |
| March 31, 2023 | 13.99M |
| December 31, 2022 | 12.81M |
| Date | Value |
|---|---|
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.231M |
| September 30, 2021 | 0.453M |
| June 30, 2021 | 0.242M |
| March 31, 2021 | 0.361M |
| December 31, 2020 | 0.476M |
| September 30, 2020 | 0.586M |
| June 30, 2020 | 0.692M |
| March 31, 2020 | 76.52M |
| December 31, 2019 | 25.80M |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Incyte Corp. | 32.68M |
| Nurix Therapeutics, Inc. | 54.92M |
| ACADIA Pharmaceuticals, Inc. | 59.55M |
| Alnylam Pharmaceuticals, Inc. | 2.942B |
| Anika Therapeutics, Inc. | 23.32M |